Mini-Reviews in Medicinal Chemistry
September 18, 2026
Fatemeh Abolhasani, Hojjat Rezaiezadeh, Mohammad Amin Langarizadeh et al.
Psilocybin, a compound found in certain species of Psilocybe mushrooms, shows potential as a treatment for various psychiatric conditions. In the past decade, a growing body of evidence has shown the effectiveness of psilocybin in treating conditions, such as treatment-resistant depression, generalized anxiety disorder, post-traumatic stress disorder, and substance use disorders. This review...
Journal of Pain and Symptom Management
September 18, 2026
Megan Miller, Molly Meyers, Candace Oglesby-Adepoju et al.
Psilocybin-assisted therapy (PAT) shows promise for alleviating psychological and existential distress among people with cancer; however, research is limited by homogeneous samples, raising concerns about generalizability and equity. To explore perceptions and attitudes of PAT among a subset of people with cancer who have been underrepresented in research. A qualitative descriptive study was...
Molecular Psychiatry
September 17, 2026
James J Gattuso, Bilgenur Bezcioglu, Jenna Hendey et al.
Obsessive-compulsive disorder (OCD) remains difficult to treat, and evidence indicates that social dysfunction, common across obsessive-compulsive and related disorders, is an under-recognized clinical burden. SAPAP3 knockout (KO) mice, a well-established model of compulsive behavior, exhibit social abnormalities, suggesting broader disruptions in circuits relevant to social cognition. Here, we...
npj Mental Health Research
September 16, 2026
Orly Lipsitz, Ryan M Brudner, Zoe Doyle et al.
Cluster B personality disorders (PDs) are highly comorbid with depression and are associated with attenuated antidepressant response. No clinical trials to date have reported on psilocybin-assisted psychotherapy (PAP) in comorbid treatment-resistant depression (TRD) and PDs. This is the first clinical trial to describe a subgroup of ten participants with a comorbid PD ( n = 9 cluster B; n = 1...
Frontiers in Psychiatry
September 15, 2026
Serena Chiara Civardi, Filippo Besana, Federico Durbano et al.
Background Treatment-resistant depression (TRD) is a major clinical challenge, with many patients failing to respond to conventional antidepressants. Psychedelic compounds such as psilocybin and ayahuasca have recently gained attention as potential rapid-acting therapies. Beyond their neurobiological effects, methodological, ethical, and real-world applicability concerns are critical for...
Chinese medical journal
September 15, 2026
Yingjie Du, Xiangting Zhao, Quan Chen et al.
Psilocybin facilitates fear extinction in rodents, but its clinical utility is hampered by 5-hydroxytryptamine (5-HT) 2A-receptor-mediated hallucinogenic effects. This study aimed to explore whether 5-HT2A receptor is obligatory for psilocybin's fear extinction and neuroplasticity effect. Male C57BL/6J mice underwent auditory-cue fear conditioning. Ketanserin (5-HT2A/2C antagonist) or MDL100907...
Zenodo (CERN European Organization for Nuclear Research)
September 14, 2026
Shaun Robinson
preprint
Psilocybin and related psychedelics can induce transient states of increased neural variability, context sensitivity, and plasticity-associated signaling. We hypothesize that selected companion botanicals can be composed with psilocybin to create a reproducible physiological and experiential lens, a botanical context, that biases the qualitative trajectory of the psychedelic state without...
Anesthesia Research
September 11, 2026
M. S. Neves, C. T. P. Gusmão, Raimundo Chiyo et al.
Background/Objectives: Neuropathic and chronic centralized pain disorders remain difficult to treat because they involve central sensitization, maladaptive neuroplasticity, neuroimmune activation, affective amplification, and large-scale network dysfunction. Psilocybin, a serotonergic psychedelic acting primarily through 5-HT2A receptor agonism, has emerged as a candidate modulator of chronic...
JAMA
September 10, 2026
Kristin L. Walter
This JAMA Patient Page describes the psychedelic compound psilocybin, its medical and recreational use, and its potential side effects.
International Journal of Molecular Sciences
September 10, 2026
Xizhen Zhang, Xiaowen Zhang, Haiyu Zhang et al.
Depression, characterized by persistent low mood and anhedonia, represents a prevalent affective disorder imposing substantial medical and economic burdens. Current first-line antidepressants are limited by delayed onset and treatment resistance. Psilocybin (PSI) has re-emerged as a promising therapeutic agent with rapid, sustained antidepressant effects. This systematic review was conducted...